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this study aimed to design and functionally characterize peptide mimetics of the nanobody (nb) 
related to the β2-adrenergic receptor (β2-AR) (nanobody-derived peptide, nDp). We postulated that 
the computationally derived and optimized complementarity-determining region 3 (CDR3) of Nb is 
sufficient for its interaction with receptor. Sequence-related Nb-families preferring the agonist-bound 
active conformation of β2-AR were analysed using the informational spectrum method (ISM) and β2-
AR:nDp complexes studied using protein-peptide docking and molecular dynamics (MD) simulations 
in conjunction with metadynamics calculations of free energy binding. The selected NDP of Nb71, 
designated P3, was 17 amino acids long and included CDR3. Metadynamics calculations yielded a 
binding free energy for the β2-AR:P3 complex of ΔG = (−7.23 ± 0.04) kcal/mol, or a Kd of (7.9 ± 0.5) 
μM, for t = 310 K. In vitro circular dichroism (cD) spectropolarimetry and microscale thermophoresis 
(MST) data provided additional evidence for P3 interaction with agonist-activated β2-AR, which 
displayed ~10-fold higher affinity for P3 than the unstimulated receptor (MST-derived EC50 of 3.57 µM 
vs. 58.22 µM), while its ability to inhibit the agonist-induced interaction of β2-AR with β-arrestin 2 was 
less evident. In summary, theoretical and experimental evidence indicated that P3 preferentially binds 
agonist-activated β2-AR.
Nanobodies (Nbs) are recombinant, antigen-specific, single-domain, variable fragments of camelid 
heavy-chain-only antibodies with a broad range of diagnostic, therapeutic and research applications1, including 
studies of G-protein-coupled receptors (GPCRs). GPCRs comprise the largest family of cell-surface receptors, 
as well as the most intensively studied drug target family, with implications in almost every major disease cate-
gory2. In particular, GPCR crystallography has experienced impressive progress in recent years. Since the struc-
tures of rhodopsin and β2-adrenergic receptor (β2-AR) were resolved in 20003 and 20074,5, respectively, over 200 
structures of more than 50 GPCRs have been solved (reviewed in6); yet data about the conformational changes 
associated with their activation is still sparse. As the biological activity induced by the binding of a ligand to 
orthosteric or allosteric sites on a GPCR is mediated by the stabilization of specific receptor conformations7, 
the emerging theme in GPCR activation/signalling is the role of the structural conformation of the receptor in 
G-protein/effector protein selection. The approaches used to obtain detailed descriptions of GPCR activation 
dynamics include molecular simulations and the use of Nbs that bind conformational epitopes, which occur only 
in native proteins8,9. Nbs were instrumental in solving (i) the first structure of activated β2-AR in complex with 
the Nb designated Nb80 and slowly dissociating agonist BI16710710, (ii) agonist-occupied β2-AR:Gs heterotrimer 
complex10 and (iii) β2-AR in complex with its low-affinity agonist adrenaline and the nanobody Nb6B9, which 
exhibited improved affinity and slower dissociation11. The same approach also facilitated the crystallization of 
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agonist-bound active-state structures of other GPCRs (for reviews see8,12,13). Additionally, β2-AR-specific Nbs 
transiently expressed as “intrabodies” in HEK-293 cells retain their conformational specificity and have been 
used as a tool to study GPCR signalling via G-protein and β-arrestin recruitment14. Nbs that stabilize the active 
conformation, such as Nb80, bind to the intracellular domain of a GPCR that is otherwise occupied by Gα sub-
unit or β-arrestin15, primarily through the third complementarity-determining region (CDR3), whereas CDR1 
should stabilize only this interaction16. Therefore, we hypothesized that approximately only 25% of the length of 
original Nbs that is computationally derived and optimized is sufficient for its interaction with the receptor. The 
main objective of our study was, therefore, the computational design and functional characterization of peptide 
mimetics of the Nb CDR3 related to β2-AR, i.e., Nb-derived peptides (NDPs). We used the following computa-
tional approaches to test our hypothesis: (i) the informational spectrum method (ISM), a virtual spectroscopy 
method for investigations of protein-protein interactions and the structure/function relationship of proteins17,18 
to design NDPs and to arrange a sequence of amino acids of NDPs that are functionally related to Nbs from 
the camelid family that are related to β2-AR, with reference to the informational properties of Nbs; (ii) explicit 
membrane molecular dynamics (MD) of derived NDPs docked into the intracellular space of the β2-AR active 
conformation to compute the protein-peptide binding free energy; and (iii) a novel computational approach in 
molecular dynamics stimulation that was introduced in 2002, known as metadynamics19,20 and implemented in 
the NAMD program21 with a CHARMM27 force field22,23, to examine the whole molecular conformational space 
and calculate the free energy during MD simulation. One selected computationally characterized NDP was then 
experimentally tested (i) by assessing its ability to bind β2-AR using techniques for studying protein-protein 
interactions, i.e., circular dichroism (CD) spectroscopy to detect changes in the conformation of interacting pro-
teins24 and microscale thermophoresis (MST), a powerful analytical technique for characterizing biomolecular 
interactions based on the movement of molecules in microscopic temperature gradients (reviewed in25); and 
(ii) by interfering with its function using the previously developed bioluminescence resonance energy trans-
fer (BRET)-based β-arrestin 2 recruitment assay26. Based on our results, molecular simulation-based theoreti-
cal calculations of binding free energy values are highly consistent with the experimental data, particularly the 
MST-derived half-maximal effective concentration (EC50) of the derived P3 for the agonist-activated β2-AR.
Results and Discussion
ISM analysis of Nbs and the interaction between β2-AR and nbs. ISM was employed to identify 
common informational characteristics of Nbs in terms of their preference for agonist-occupied β2-AR and infor-
mation about the characteristics of the interaction between β2-AR and the Nbs, as well as to identify the key 
domain of Nb involved in receptor targeting (Fig. 1). Based on CDR3 conservation, β2-AR Nbs were classified 
into four distinct families [A, B, C, and miscellaneous (MISC)]. Nbs that showed a clear preference for agonist 
(BI-167107)-occupied β2-AR belonged to family B14. Here, we analysed the extensively characterized Nb80 from 
family B that binds agonist-activated β2-AR10 and Nb84 and Nb71 from Nb families C and MISC, respectively, the 
latter two of which display a preference for binding active β2-AR conformations14. Common biological character-
istics of the group of proteins that share common information are represented by peaks in their consensus infor-
mational spectrum (CIS)18. A cross-spectral analysis of Nbs stabilizing an active β2-AR conformation showed 
that Nbs shared common information corresponding to the informational spectrum (IS) frequency F(0.216) 
(Fig. 1a). An ISM analysis of individual spectra of Nbs that bound the β2-AR only in the presence of agonist, Nb80 
and Nb71 (Fig. 1b), revealed the same dominant IS peak at the frequency F(0.216) in both individual spectra. 
Furthermore, we performed a cross-spectral analysis of β2-AR and Nb71 and identified that these two molecules 
shared the same common information corresponding to the IS frequency F(0.216), indicating their interaction 
(Fig. 1c). This finding prompted us to speculate that the common information for Nbs is also the most important 
for the interaction of Nb71 with the β2-AR. In a subsequent analysis, we wanted to determine the Nb domains 
that were most important for the identified information feature because they would be a key part of the Nb in its 
interaction with the receptor. We assumed that this isolated portion of the Nb would be sufficient for the interac-
tion with the β2-AR and for stabilizing an active receptor conformation.
Identification of the key protein domain responsible for the interaction between β2-AR and 
nbs. Next, a computational peptide scanning analysis was performed to define linear protein regions of the 
β2-AR that exhibited the greatest contributions to the amplitude and signal-to-noise ratio at the characteristic fre-
quency and therefore were responsible for the interaction(s) described by the particular spectral characteristic. By 
performing computational peptide scanning of Nb71 at F(0.216), we identified the region encompassing amino 
acid residues (aar) 88–104 (Fig. 2a) as essential for the information represented by this frequency. The identified 
domain of Nb, denoted by P3, was the key domain responsible for the interaction with the receptor. It was a 
peptide of 17 aa, EDTAVYYCNANWDLLSD. As shown in Fig. 2b, P3 had an amino acid sequence that reflected 
common informational properties shared with Nb71. The identified NDP was proposed to be a mimetic of Nb71 
and assumed sufficient for the interaction with the agonist-bound β2-AR and for stabilizing an active receptor 
conformation. P3 is located inside CDR3, consistent with some previous findings. First, highly diverse CDR3 
regions in all antigen receptors are suggested to be the key determinants of specificity in antigen recognition27. 
Second, an antibody uses only a single loop, its CDR3, to interact directly with the antigen28. Because CDR3 
within Nb80 is responsible for most of the binding interactions16 and because the peptidomimetics of the CDR3 
loop were likely sufficient for binding to the receptor and inhibiting the interaction of β2-AR with its intracellular 
GPCR-interacting proteins, such as Gαs and β-arrestins, the peptidomimetics of CDR3 structurally mimicked 
the CDR3 loop of an Nb29.
Molecular docking of peptides. CABS-dock docking results were the output of the 1,000 top conforma-
tions of β2-AR-peptide complexes, along with the 10 best and individual trajectories for each final conformation. 
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We chose a complex where the peptide was docked in the intracellular loop using the β2-AR-Nb80 binding pat-
tern as a reference. The list of aar and interactions observed in the β2-AR-Nb80 complex (PDB 3P0G crystal struc-
ture)16 are presented in Table 1. These data guided us in selecting properly docked conformations of our peptides. 
Finally, the best conformations of our four peptides were isolated. Since only one (P3) out of four peptides had 
reported experimental activity, only P3 data are presented. However, the sole use of flexible ligand docking is not 
Figure 1. Bioinformatics analysis of Nbs and β2-AR and Nb71 using ISM. (a) Cross-spectral analysis (CIS) of 
Nb80, Nb84 and Nb71 stabilizing the active conformation of β2-AR, with the characteristic peak at F(0.216).  
(b) IS of Nb71 and (c) CS of β2-AR and Nb71. The CS of β2-AR and Nb71 showed a common peak 
corresponding to the IS frequency F(0.216).
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the most reliable method to estimate complex stability and ligand binding affinity; therefore, the obtained com-
plexes were subjected to MD simulations and free energy calculations.
MD simulations. A prepared complex of β2-AR:P3 was subjected to MD simulations to determine its stabil-
ity. Its structure is shown in Fig. 3. During the 100 ns of the production phase, the β2-AR:P3 complex remained 
stable and intermolecular interactions persisted, with eventual breaking and re-arranging on peptide terminals 
due to its flexibility. The interactions observed in the β2-AR:P3 complex are presented in Fig. 4a and Table 2. 
The total energy plot and the RMSD plots of both the receptor and peptide showed convergence of the system 
(Supplementary Figs S1–3). MD alone is neither sufficient to identify the proper conformation of the ligand nor 
to estimate its affinity for the receptor, and it should be combined with one of the methods used to calculate free 
energy. The basic idea behind the free energy calculations is to calculate the probability density along the postu-
lated reaction coordinate, and typically, biased sampling is required. Therefore, the next logical step was to select a 
method that systematically explored the conformational space of the peptide and receptor to calculate their bind-
ing free energy values. For that purpose, we chose metadynamics19,30, which has also been successfully applied in 
bimolecular simulations dedicated to the study of protein-protein interactions (reviewed in20).
Metadynamics simulations. We performed well-tempered metadynamics simulations of the β2-AR:P3 
complex after the MD production phase to estimate the binding free energy between β2-AR and the peptide. For 
the centroid of β2-AR aar, we chose the backbone carbon atoms Arg63, Asn69, Arg131, Ile135, Tyr141, Thr274, 
Ser329 and Pro330. We chose all residues of the peptide. The initial distance between the two centroids in the 
docked conformation was 4,890 Å, and we altered this distance by up to 60 Å. The choice of protocol was not 
trivial, and the main reason was the flexibility of the peptide ligand. The peptide itself possessed high flexibility, 
giving rise to slow equilibration and a noisy potential of mean force (PMF). After numerous preliminary meta-
dynamics simulation experiments, we concluded that extraction of the peptide to an intracellular water layer 
Figure 2. Mapping of the putative interaction sites of β2-AR and Nb71. (a) Position of the domain in the 
primary structure of Nb71 (residues 88–104). (b) The IS of P3, which is 17 aa long.
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along the z-axis of the system, parallel to the axis of the receptor and perpendicular to the cell membrane was an 
appropriate protocol. A good starting peptide conformation was identified by assessing its conformation after 
100 ns of production where the P3 preserved its orientation and a similar binding pattern that between β2-AR 
and Nb80. (Fig. 4a,b, Tables 1 and 2). For further confirmation of stability after the production phase, we plotted 
the RMSD values of receptor and peptide (Supplementary Figs S2 and 3). Regarding the stability of β2-AR during 
the production and metadynamics phases, we plotted the distance between the backbone carbon atoms of Trp68 
(TM3) and Ala271 (TM6) during production and the metadynamics phase (Supplementary Figs S4 and 5), the 
RMSDs of the receptor and the total energy profile (Supplementary Figs S6 and 7). The changes in distance during 
both phases showed the stability of the active conformation, and the values were within the limits of the reference 
values: 10.766 Å for the inactive conformation and 18.084 Å for the active conformation of β2-AR (values from 
PDB structures 2RH1 and 3P0G, respectively).
The distance evolution, i.e., its projection on the z-axis between receptor and peptide, is presented in Fig. 5. 
Regarding the PMF energy profile, the PMF energy initially increased to ~15 kcal/mol until the distance reached 
approximately 17 Å in the initial bound conformation as shown in Fig. 6. This energy change originated from the 
breaking of non-bonded interactions between aar of the receptor and peptide and peptide stretching due to the 
applied force on the peptide and its flexibility. During metadynamics, receptor-peptide interactions are gradually 
broken and re-formed. Peptide conformational changes increases the conformational energy, resulting in a very 
noisy PMF output. After the distance exceeds 17 Å, the PMF slowly decreases because of complete transfer of the 
peptide to the unbound form and convergence of the internal conformational energy of the peptide, forming a 
stable PMF area between 20 and 30 Å. After pushing the peptide to the upper boundary, the PMF energy contin-
ues to rise as a result of continuous peptide stretching. Afterwards, the peptide is shifted to the upper cell bound-
ary and remains there (Fig. 5). The PMF profile is presented in Fig. 6. The binding free energy value is the negative 
difference between the initial and final states of PMF evolution. We averaged the stable PMF area between 20 
and 30 Å to calculate the binding free energy while avoiding metadynamics artefacts and eliminating noise in the 
energy. The corresponding PMF difference, according to descriptive statistical analysis, was 7.23 kcal/mol; i.e., we 
estimated the binding free energy of the β2-AR:P3 complex as ΔG = −7.23 kcal/mol, or Ki = 7.9 μM at 310 K. The 
standard error of the calculation was 0.04 kcal/mol, so the final result was written as ΔG = (−7.23 ± 0.04) kcal/
mol, or Kd = (7.9 ± 0.5) μM.
The peptide conformational energy minima were meant to be achieved during the 100 ns simulation time. 
However, due to high conformational freedom of the peptide producing a noisy PMF profile, we had no choice but 
to select an area within approximately 20 to 30 Å to average the PMF, as it represents the unbound peptide form. 
The complete metadynamics simulation movie is in Supplementary Material S8, and the non-peptide-bound 
form is observed at approximately 00:00:07. We are aware that convergence of PMF cannot be reached using 
only one starting peptide conformation and only one binding/unbinding event, but the good agreement with 
Name Distance Category Type From
From 
Chemistry To To Chemistry
Angle 
XDA
Angle 
DAY Theta Theta22 Gamma
Closest 
Atom 
Distance
A:ARG131:NH2-
B:GLU106:OE2 4.55504 Electrostatic
Attractive 
Charge A:ARG131:NH2 Positive B:GLU106:OE2 Negative
A:ARG131:CD-
B:VAL103:O 2.7792 Hydrogen Bond
Carbon 
Hydrogen 
Bond
A:ARG131:CD H-Donor B:VAL103:O H-Acceptor 96.039 138.559
B:SER30:CB-A:ALA226:O 3.76186 Hydrogen Bond
Carbon 
Hydrogen 
Bond
B:SER30:CB H-Donor A:ALA226:O H-Acceptor 94.333 136.361
B:HIS52:CE1-A:ILE135:O 2.95275 Hydrogen Bond
Carbon 
Hydrogen 
Bond
B:HIS52:CE1 H-Donor A:ILE135:O H-Acceptor 102.029 165.557
A:ARG328:C,O;SER329:N-
B:TYR105 4.42188 Hydrophobic
Amide-Pi 
Stacked A:ARG328:C,O;SER329:N Amide B:TYR105 Pi-Orbitals 31.609 30.163 12.821 3.962
A:ARG131-B:LEU104 5.45175 Hydrophobic Alkyl A:ARG131 Alkyl B:LEU104 Alkyl
A:VAL222-B:VAL103 5.4757 Hydrophobic Alkyl A:VAL222 Alkyl B:VAL103 Alkyl
A:ALA226-B:ILE31 5.16574 Hydrophobic Alkyl A:ALA226 Alkyl B:ILE31 Alkyl
A:ILE278-B:LEU104 5.27015 Hydrophobic Alkyl A:ILE278 Alkyl B:LEU104 Alkyl
B:VAL103-A:LEU275 4.88306 Hydrophobic Alkyl B:VAL103 Alkyl A:LEU275 Alkyl
A:PHE139-B:ALA50 4.74445 Hydrophobic Pi-Alkyl A:PHE139 Pi-Orbitals B:ALA50 Alkyl
A:TYR326-B:LEU104 5.19168 Hydrophobic Pi-Alkyl A:TYR326 Pi-Orbitals B:LEU104 Alkyl
B:PHE29-A:ALA226 5.29543 Hydrophobic Pi-Alkyl B:PHE29 Pi-Orbitals A:ALA226 Alkyl
B:PHE29-A:ALA271 4.40895 Hydrophobic Pi-Alkyl B:PHE29 Pi-Orbitals A:ALA271 Alkyl
B:HIS52-A:PRO138 4.67849 Hydrophobic Pi-Alkyl B:HIS52 Pi-Orbitals A:PRO138 Alkyl
B:TYR100-A:ILE135 5.39955 Hydrophobic Pi-Alkyl B:TYR100 Pi-Orbitals A:ILE135 Alkyl
B:TYR105-A:PRO330 5.27514 Hydrophobic Pi-Alkyl B:TYR105 Pi-Orbitals A:PRO330 Alkyl
Table 1. Interactions between Nb80 and β2-AR from the PDB structure 3P0G (A chain represents β2-AR, and B 
chain represents peptide).
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experimental results (MST and BRET) and limited access to GPU resources prompted us to keep this approach 
and consider the obtained result as acceptable. In this respect, we considered the calculated potential of mean 
force as semiquantitative. We feel that for fully converged potential of mean force one would require a simulation 
length of several tens of microseconds, which exceeds available computer power.
In subsequent steps, we attempted to provide experimental evidence for the computationally characterized 
interaction between the β2-AR and P3.
circular dichroism (cD). Based on the CD spectra for P3 recorded in the far-UV range, this peptide does 
not have a distinctive secondary structure and is rather unstructured (Fig. 7, dark blue line). Experimental evi-
dence from CD spectropolarimetry for the computationally characterized interaction between β2-AR and P3 is 
presented in Fig. 7. Cell lysates from untransfected (control) HEK-293 cells and HEK-293 cells transfected with 
β2-AR/Rluc8 were titrated with P3 in the presence or absence of the β2-AR agonist isoproterenol. Comparison of 
the graphs in Fig. 7 reveals that P3 strongly interacted with cell lysates prepared from β2-AR/Rluc8-transfected 
HEK-293 cells that were preincubated with the β2-AR agonist isoproterenol (Fig. 7a) relative to its interaction 
with lysates from either unstimulated β2-AR transfected HEK-293 cells (Fig. 7b) or isoproterenol-stimulated, 
untransfected HEK cells (Fig. 7c). This claim is based on the hypothesis that all P3 is bound to β2-AR and then 
the complex contributes to the entire CD signal. In the case of HEK-293 cells, a high contribution of free P3 to the 
CD signal was shown at P3 concentrations ≥20 µM (Fig. 7c), particularly at wavelengths below 214 nm. We also 
Figure 3. Structure of the β2-AR receptor in complex with the cocrystallized agonist P0G (8-[(1R)-2–1-
hydroxyethyl]-5-hydroxy-2H-1,4-benzoxazin-3(4H)-one) and the docked peptide P3, prepared for the MD 
simulation.
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concluded that the induced CD signal was higher when β2-AR-transfected HEK-293 cells were pretreated with 
agonist than in unstimulated cells (cf. panels a and b in Fig. 7). The only difference between the untransfected and 
β2-AR-transfected HEK-293 cells was that the level of β2-AR was significantly higher in transfected HEK-293 cells 
(confirmed by total luminescence measurements) than in untransfected HEK-293 cells, in which low endogenous 
expression of the β2-AR was indicated by the very sensitive cAMP ALPHAscreenTM assay31 and the low expression 
of the β2-AR mRNA32.
Microscale thermophoresis (MSt) data. Next, we used the recently developed MST method to quantify 
β2-AR:P3 interactions. Measurements were performed directly in cell lysates prepared from HEK-293 cells tran-
siently transfected with β2-AR tagged with the green fluorescent protein 2 (β2-AR/GFP2), without the need for a 
prior protein purification/labelling step. MST-derived dose-response curves for the interactions of isoproterenol 
and P3 with β2-AR are shown in Fig. 8. The EC50 of the well-validated β-adrenoceptor agonist isoproterenol for 
β2-AR was in the submicromolar range, i.e., 0.275 ± 0.065 µM, which corresponded well to the relatively low affin-
ity of β2-AR agonists10. On the other hand, P3 displayed EC50 values of 58.22 ± 13.59 µM and 3.57 ± 0.81 µM for 
non-activated and agonist-activated β2-AR, respectively. Isoproterenol-activated β2-AR thus displayed an approx-
imately 10-fold higher affinity for P3 than unstimulated β2-AR (Fig. 8b), corroborating the calculated Ki (7.9 μM) 
obtained from the metadynamics simulation. This finding is also consistent with the CD spectropolarimetry 
observations and provides additional experimental evidence for the preference of P3 for agonist-activated β2-AR. 
Similarly, Nb80 efficiently binds to only agonist-occupied β2-AR10.
BRet2-based β-arrestin 2 recruitment assay. Because the protein-peptide binding energies of the 
β2-AR:P3 complex and MST predicted a micromolar-range interaction of P3 with the agonist-activated β2-AR, we 
next evaluated the ability of P3 to interfere with the agonist-induced interaction of β2-AR with β-arrestin 2, as P3 
and β-arrestin 2 should compete for the same binding site, and Nb71, which was used as the model to derive P3, is 
a powerful inhibitor of β-arrestin recruitment to β2-AR14. Due to the hydrophilic nature of P3 and its presumptive 
binding to the intracellular receptor site, we modified the previously developed BRET-based β-arrestin 2 recruit-
ment assay26 to enable P3 to bind to β2-AR. Therefore, we used either homogenized or Triton-X100-permeabilized 
cells (Fig. 9) instead of whole cells. First, previously characterized β2-AR ligands were tested to validate our modi-
fied BRET2 assay. The maximal agonist-induced BRET signal (BRETmax) was reduced by approximately 50% when 
the experiment was performed with homogenized or permeabilized cells relative to the maximal signal when the 
experiment was performed with whole cells (BRETmax of ≈40 vs. 80 mBU), whereas the potency of isoproterenol 
and pindolol remained comparable among the various conditions (see panels a and b in Fig. 9). The obtained 
BRET2 EC50 values for the isoproterenol-induced interaction of the β-arrestin 2 Arg393Glu, Arg395Glu mutant 
with β2-AR (13.65 ± 1.98, 28.89 ± 1.98 and 13.74 ± 1.37 nM in whole, homogenized and permeabilized cells, 
respectively) were also highly consistent with previously reported data26. Figure 9b shows the BRET2 antagonist 
dose-response curves generated in the presence of increasing concentrations of the adrenergic receptor antago-
nist pindolol. The potency of pindolol (IC50 of 1.49 ± 0.07, 3.76 ± 0.08 and 2.24 ± 0.22 nM in whole, homogenized 
and permeabilized cells, respectively) at inhibiting the isoproterenol-induced BRET2 signal was consistent with 
a previously reported range26. The hydrophilic NDP P3 showed no effect on the isoproterenol-induced BRET2 
signal in whole cells, but when either homogenized or permeabilized cells were used, the peptide caused a small 
dose-dependent reduction (up to 10%) in the isoproterenol-induced BRET2 signal (Fig. 9c), with an estimated 
EC50 in a low-nanomolar range, i.e., ~1 nM. We presumed that the inability of P3 to effectively compete with 
β-arrestin 2 for the same binding site was due to its reduced size (less than 25% of the length of the original Nb). 
Researchers have also postulated that Nb71 inhibits agonist-mediated β-arrestin recruitment to the β2-AR by 
blocking receptor phosphorylation14. Therefore, we also hypothesized that the computationally derived NDP of 
the Nb71 CDR3 is not able to block receptor phosphorylation. The β-arrestin 2 Arg393Glu, Arg395Glu mutant 
Figure 4. Conformation of (a) the docked peptide in β2-AR after the first 100 ns production phase and (b) 
Nb80 in β2-AR. Marked interactions are the same as observed in the β2-AR-Nb80 crystal structure. Orange: 
electrostatic interactions; purple/grey: hydrophobic interactions. Amino acid residues shown in black belong to 
the β2-AR, while green residues belong to P3.
8Scientific RepoRtS |         (2019) 9:16555  | https://doi.org/10.1038/s41598-019-52934-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
used in our study should bind to the receptor regardless of its phosphorylation status due to the reversed charge 
of an amino acid in the polar core (Arg393Glu)33,34, and this mutation prolongs the lifetime of the receptor:β-arr2 
complex due to disruption of β-arrestin 2:AP-2 binding (Arg395Glu34). Similarly, peptidomimetics of the Nb80 
Name Distance Category Type From From Chemistry To To Chemistry Angle XDA Angle DAY
A:LYS267:HZ1-
B:ASP301:OT1 1.73647
Hydrogen Bond; 
Electrostatic
Salt Bridge; 
Attractive Charge A:LYS267:HZ1
H-Donor; 
Positive B:ASP301:OT1
H-Acceptor; 
Negative 156.026 98.442
A:LYS267:HZ3-
B:ASP301:OD1 2.10006
Hydrogen Bond; 
Electrostatic
Salt Bridge; 
Attractive Charge A:LYS267:HZ3
H-Donor; 
Positive B:ASP301:OD1
H-Acceptor; 
Negative 114.335 101.005
A:ARG131:NH1-
B:ASP297:OD2 5.09788 Electrostatic Attractive Charge A:ARG131:NH1 Positive B:ASP297:OD2 Negative
A:LYS147:NZ-
B:ASP286:OD1 4.64041 Electrostatic Attractive Charge A:LYS147:NZ Positive B:ASP286:OD1 Negative
A:LYS267:NZ-
B:ASP301:OT2 4.06921 Electrostatic Attractive Charge A:LYS267:NZ Positive B:ASP301:OT2 Negative
A:ARG131:HH12-
B:TRP296:O 1.76198 Hydrogen Bond
Conventional 
Hydrogen Bond A:ARG131:HH12 H-Donor B:TRP296:O H-Acceptor 165.137 162.749
A:LYS147:HN-
B:ASP286:OD2 1.75273 Hydrogen Bond
Conventional 
Hydrogen Bond A:LYS147:HN H-Donor B:ASP286:OD2 H-Acceptor 167.533 133.069
A:SER329:HG1-
B:CYS292:O 1.73294 Hydrogen Bond
Conventional 
Hydrogen Bond A:SER329:HG1 H-Donor B:CYS292:O H-Acceptor 168.889 131.481
B:TYR290:HH-
A:ASP331:OD2 1.62197 Hydrogen Bond
Conventional 
Hydrogen Bond B:TYR290:HH H-Donor A:ASP331:OD2 H-Acceptor 167.973 111.859
A:ARG131:HD1-
B:ASN295:OD1 2.38653 Hydrogen Bond
Carbon 
Hydrogen Bond A:ARG131:HD1 H-Donor B:ASN295:OD1 H-Acceptor 159.279 95.278
A:ARG131:HD2-
B:TRP296:O 2.61421 Hydrogen Bond
Carbon 
Hydrogen Bond A:ARG131:HD2 H-Donor B:TRP296:O H-Acceptor 120.492 142.836
A:THR146:HA-
B:ASP286:OD2 2.46319 Hydrogen Bond
Carbon 
Hydrogen Bond A:THR146:HA H-Donor B:ASP286:OD2 H-Acceptor 135.275 147.36
A:SER329:HB1-
B:ASN293:O 2.75817 Hydrogen Bond
Carbon 
Hydrogen Bond A:SER329:HB1 H-Donor B:ASN293:O H-Acceptor 134.877 117.807
A:SER329:HB2-
B:CYS292:O 2.99923 Hydrogen Bond
Carbon 
Hydrogen Bond A:SER329:HB2 H-Donor B:CYS292:O H-Acceptor 91.116 163.907
B:CYS292:HA-
A:ASP331:OD2 2.74226 Hydrogen Bond
Carbon 
Hydrogen Bond B:CYS292:HA H-Donor A:ASP331:OD2 H-Acceptor 160.083 113.094
A:ARG63-
B:CYS292 4.49915 Hydrophobic Alkyl A:ARG63 Alkyl B:CYS292 Alkyl
A:ILE135-
B:LEU298 5.36325 Hydrophobic Alkyl A:ILE135 Alkyl B:LEU298 Alkyl
A:PRO138-
B:LEU299 4.86055 Hydrophobic Alkyl A:PRO138 Alkyl B:LEU299 Alkyl
A:ALA226-
B:LEU298 4.37024 Hydrophobic Alkyl A:ALA226 Alkyl B:LEU298 Alkyl
A:ALA271-
B:LEU298 5.18113 Hydrophobic Alkyl A:ALA271 Alkyl B:LEU298 Alkyl
B:CYS292-
A:LEU64 4.90786 Hydrophobic Alkyl B:CYS292 Alkyl A:LEU64 Alkyl
B:ALA294-
A:ILE72 4.72223 Hydrophobic Alkyl B:ALA294 Alkyl A:ILE72 Alkyl
A:PHE332-
B:ALA294 5.11125 Hydrophobic Pi-Alkyl A:PHE332 Pi-Orbitals B:ALA294 Alkyl
B:TRP296-
A:ARG131 4.40471 Hydrophobic Pi-Alkyl B:TRP296 Pi-Orbitals A:ARG131 Alkyl
B:TRP296-
A:LEU275 5.07559 Hydrophobic Pi-Alkyl B:TRP296 Pi-Orbitals A:LEU275 Alkyl
B:TRP296-
A:ARG131 3.87722 Hydrophobic Pi-Alkyl B:TRP296 Pi-Orbitals A:ARG131 Alkyl
B:TRP296-
A:LEU275 4.60971 Hydrophobic Pi-Alkyl B:TRP296 Pi-Orbitals A:LEU275 Alkyl
Table 2. Interactions between β2-AR and P3 after 100 ns of production. A chain: β2-AR, B chain: peptide.
Figure 5. β2-AR:P3 distance evolution during metadynamics simulation.
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CDR3 loop were recently shown to only moderately inhibit isoproterenol-induced cAMP production29, suggest-
ing that additional residues outside the CDR3 loop are important for effective interference with the Gα/β-arrestin 
interactions. Alternatively, the relative inefficiency of P3 in the BRET recruitment assay might have been due to 
the lower affinity of P3 (micromolar range) than purified β-arrestin for phosphorylated β2-AR, which is in the 
nanomolar range (a reported Kd of 1.8 nM)35.
In summary, this study presents evidence obtained from a combination of computer-based methodological 
approaches supported by in vitro experimental data used to design and characterize NDPs. It is a small step 
towards obtaining a better understanding of GPCR dynamics at the molecular level in the context of GPCR inter-
actions with their protein partners. The combined use of experimental and computational techniques represents 
Figure 6. Evolution of potential of mean force during the metadynamics simulation of the initially docked 
peptide conformation.
Figure 7. CD spectra of cell lysates prepared from β2-AR-transfected/untransfected HEK-293 cells incubated 
with different concentrations of P3 in the presence or absence of the agonist isoproterenol. Lysates of HEK-
293 cells transiently transfected with β2-AR/Rluc8 (a and b) and mock-transfected (control) HEK-293 cells (c) 
were titrated with P3 in the presence (a,c) or absence of the β2-AR agonist isoproterenol (b). In the presence of 
agonist, the cell lysate was preincubated with 1 µM isoproterenol, and then P3 was added at a final concentration 
of 5, 10, 20 or 30 µM. The CD spectrum of P3 (P3, dark blue line) in buffer is shown for comparison. All 
experiments were performed in PBS, pH 7.2, containing 0.1% DMSO at 25 °C.
Figure 8. Detection of the interaction of P3 with the β2-AR using MST. In the MST experiment, the 
concentration of β2-AR/GFP2 was maintained at a constant value by adding equal amounts of cell lysate while 
increasing the concentration of the known β2-AR agonist isoproterenol (control, panel a) or tested NDP, i.e., 
P3, in the absence (panel b, solid line) or presence of 10 µM isoproterenol (panel b, dotted line). After a short 
incubation, the samples were centrifuged and loaded into MST NT.115 premium capillaries, and the MST 
analysis was performed using Monolith NT.115pico, as described in the Materials and Methods. The change 
in the normalized fluorescence (ΔFnorm) value of each point was divided by the amplitude of the fitted curve to 
calculate the bound fraction, resulting in values ranging from 0 to 1. Data (mean ± S.E.) were obtained from 3–5 
independent measurements.
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a powerful framework for achieving progress in this direction and could lead to further modification and optimi-
zation of NDPs as efficient modulators of GPCRs and other applications, including drug discovery and therapy.
Methods
Materials. Molecular biology and cell culture reagents for were from Sigma-Aldrich (St. Louis, MO, USA) 
and Gibco Invitrogen Corporation (Breda, The Netherlands). Pindolol and isoproterenol were from Sigma-
Aldrich. Coelenterazine 400a from Biotrend Chemikalien GmbH (Köln, Germany). Selected NDPs (P1-P4) were 
custom-synthesized at Biomatik Corporation, Cambridge, Ontario, Canada.
informational spectrum method (iSM). The principle of the ISM has been thoroughly explained18,36 
and has been successfully applied to the structure-function analysis of different proteins18, the prediction of new 
protein interactors37 and the identification of protein domains responsible for long-range interactions38.
computational peptide scanning. Computational peptide scanning was utilized to define linear protein 
regions responsible for the interaction(s) described by the particular spectral characteristic. The sequence of 
Nb71 was scanned by the ISM algorithm with overlapping windows of different lengths to identify regions with 
the highest amplitudes at the predefined Fourier frequency.
Datasets. The sequence of human β2-AR used for the bioinformatics analysis was retrieved from the UniProt 
database with accession number P07550. The sequences of Nbs are presented in US patent US20130137856 and 
the PDB entry 3P0G FASTA sequence.
Receptor preparation. The active state crystal structure of the β2-AR was obtained from the RSCB protein 
databank (PDB entry code 3P0G). All lipids, water molecules, and ions and Nb80 were removed. Only the P0G 
ligand was retained.
Molecular docking of peptides. Peptide-protein docking was conducted using the online CABS-dock 
server39. Using the given protein receptor 3D structure, binding site and peptide sequence, a docking search for 
the binding site is performed that allows for full flexibility of the peptide and small fluctuations in the receptor 
backbone. The output of the simulation is the three-dimensional coordinates of the protein in complex with the 
ligand accompanied by full docking process trajectories and CABS force field docking scores, including energies 
of the receptor, ligand and their interaction. The binding site is indirectly defined by unlikely-to-bind regions of 
β2-AR, which exclude all aar regions except intracellular loops. The number of simulation cycles was set to 50. 
The best solutions, including the peptide in the intracellular space and lowest CABS-dock energy, were selected 
for further MD simulations.
Ligand parameterization. Ligand was assigned CGenFF force field atomic charges (ParamChem)40 and 
van der Waals parameters, whereas force constants were obtained from the Hessian equation calculated after 
geometric optimization of the HF/6–31 G(d) level of theory in Gaussian 03 W41. All parameters were generated 
in the VMD Parameterize extension42.
MD simulations. The β2-AR-agonist-NDP complex, with peptide coordinates obtained from the docking 
output, was inserted into a 70 × 70 Å 2-oleoyl-1-palmitoyl-sn-glyecro-3-phosphocholine (POPC) lipid bilayer. 
A 10 Å water layer was added from the positive side of the z-axis and 60 Å from the negative side. Bad-contact 
water molecules were removed from the lipid membrane bilayer using the appropriate tcl script. Additionally, the 
system was neutralized with 0.15 M NaCl, resulting in a 61,183 (~60,000) atom ensemble. The system was subject 
to a 10,000 step energy minimization, 250 NVE ps equilibration, and 100 ns NPT MD production. Pressure and 
temperature were set to 1 bar and 310 K, respectively, using a Berendsen thermostat, and the applied integra-
tion step was 1 fs. In all simulations, periodic boundary conditions with particle-mesh Ewald calculations were 
implemented. The cut-off was set to 12 Å. A CHARMM2222,23 force field was used for protein and lipids, and 
CGenFF43,44 was used for ligands.
Figure 9. Comparison of ligand-induced BRET2 signals. HEK-293 cells were transiently transfected with β2-
AR/RLuc8 together with the GFP2/β-arr2 Arg393Glu, Arg395Glu at a 1:10 cDNA ratio, and the BRET2 assay 
was performed with whole, homogenized or Triton X-100-permeabilized cells. Increasing concentrations of (a) 
the agonist isoproterenol (10−12 to 10−5 M final concentration), (b) the antagonist pindolol (10−12 to 10−6 M final 
concentration) and isoproterenol (10 µM final concentration) or (c) P3 (10−12 to 10−5 M final concentration) 
and isoproterenol (10 µM final concentration) were added to cells, and BRET2 was measured as described in 
Materials and Methods. Data are presented as the means ± S.E. of triplicate measurements.
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Metadynamics simulation. Metadynamics is a powerful method for calculating free energy. It was initially 
developed by Laio and Parrinello19 and later improved to well-tempered metadynamics20. Before metadynamics 
simulation, one must determine the collective variables that will be varied during simulation and in regard to 
which the PMF will be calculated. We chose one variable, the distance between centroids of protein amino acid 
(aa) and peptide residues. Their atoms belonged to backbone C of the binding aar in the intracellular loops of the 
receptor and all residues in the peptide. The lower boundary (minimal distance value) was set to the initial dis-
tance between centroids of receptor-ligand atom groups, which was obtained from the coordinates of the docked 
structure optimized by MD production. The upper boundary (maximal value) was set to the distance at which 
the peptide was located sufficiently far away from the receptor in the water layer close to the side of the PBC cell. 
In this way, we ensured that no intermolecular interactions between the protein and peptide were present along 
all three coordinate axes. During our metadynamics simulation, the peptide pushed towards the intracellular 
water layer, parallel to the z-axis of the cell and perpendicular to the cell membrane. The resulting change in free 
energy between initial and equilibrated states of the peptide in the water layer was designated the binding free 
energy of the complex. Collective variable trajectory frequency (frequency of generating free energy files) was set 
to 10,000 ps. The lower wall constant (lowest value of applied force, units in kcal/(mol*A)) was set to 120.0, the 
upper wall constant (highest value of applied force) was set to 180.0, and width (the force resolution) was set to 
0.1. For the main atoms, we selected backbone carbon atoms from the receptor, and for the reference, we selected 
backbone carbon atoms from the peptide. The hill weight (amount of PMF energy that is gradually added to a 
system during simulation) was set to 0.1 kcal/mol, the hill width was set to 1.0 Å, and the new hill frequency was 
set to 100 ps. Bias temperature was set to 1550 K. All free energy files generated during simulation were collected. 
The total metadynamics simulation time was 40 ns, and the integration step was 1 fs. Descriptive statistical analy-
sis of PMF and the corresponding Figures was performed using Origin 8 (OriginLab Corporation, Northampton, 
MA, USA).
fusion constructs. Human HA-tagged β2-AR (HAβ2-AR) cDNA and human β-arrestin 2 N-terminally 
tagged with the green fluorescent protein variant 2 GFP2 (GFP2/β-arr2) were from cDNA Resource Center 
(www.cdna.org) and from BioSignal Packard Inc., Montreal, Canada, respectively. C-terminal Renilla lucif-
erase 8 (RLuc8) tagged HAβ2-AR (β2-AR/RLuc8), C-terminal GFP2-tagged β2-AR (β2-AR/GFP2) and mutant 
GFP2/β-arr2 (GFP2/β-arr2 Arg393Glu, Arg395Glu) were described in previous studies26,45,46.
cell culture and transfection. HEK-293 cells (European Collection of Animal Cell Cultures, Salisbury, 
UK) were routinely maintained and passaged as described previously45,47. Transient transfections were performed 
when cells reached ~90% confluence using the Lipofectamine®-Plus™ Reagent. The expression levels of RLuc8- 
and GFP2-tagged constructs were monitored by recording total luminescence and fluorescence as previously 
described48.
circular dichroism (cD). All CD spectra were recorded on a Jasco J-1500 spectropolarimeter at 25 °C using 
a 1 mm quartz cuvette in the UV range of 250–200 nm. The CD spectra were measured every 0.5 nm with a scan-
ning rate of 10 nm/min. Lysed cells (A280 = 1.5) (HEK-293, β2-AR/Rluc8 transfected HEK-293 cells) were dialysed 
against PBS buffer, pH 7.2, containing 1% glucose and 0.1% DMSO. P3 was solubilized in 0.1% DMSO in DPBS 
supplemented with Ca2+/Mg2+, 1 g/L glucose, and 36 mg/L sodium pyruvate buffer. The concentration of the P3 
stock solution was 1 mM. CD spectra of a 10-fold dilution of the initial cell lysate in the presence of P3 at final 
concentrations of 0, 5, 10, 20, and 30 µM were recorded. The density of HEK-293 and β2-AR/Rluc8-transfected 
HEK-293 cells were equal, as determined spectrophotometrically. In the case of agonist addition (10 µM), the cell 
lysate was incubated with agonist for 5 minutes at 25 °C before the CD spectra were recorded. Each CD spectrum 
was subtracted from the CD spectrum of the buffer.
Microscale thermophoresis (MSt). HEK-293 cells plated in a 75 cm2 flask were transiently co-transfected 
with constructs encoding β2-AR/GFP2 (5.0 μg), and cell lysates were prepared after 48 h as described below. The 
75 cm2 flasks were transferred to ice, and cells were washed once with ice-cold DPBS. Then, 750 µL of NP40 lysis 
buffer was added to each 75 cm2 flask and incubated on ice for 5 minutes. Cells were scraped from the 75 cm2 
tissue culture flasks using cell scrapers (Falcon), and detached cells were incubated on ice for an additional 
20 minutes. Cell lysates were transferred to cold 1.5 mL tubes and clarified by centrifugation (15,300 rpm for 
30 minutes at 4 °C). Next, 700 µL of cleared lysate was transferred to a new cold 1.5 mL tube, and the level of 
β2-AR/GFP2 was verified by measuring the total fluorescence. Ten microlitres of cell lysate were used as the target, 
while the non-fluorescent ligands isoproterenol and P3 were titrated in a series of 1:1 dilutions in MST buffer 
containing 0.05% Tween 20. Ten microlitres of the serial dilution of the ligand were mixed with 10 μL of the 
cell lysate. After a short incubation at room temperature, samples were centrifuged and loaded into Monolith™ 
NT.115 MST Premium Capillaries (NanoTemper Technologies GmbH, Munich, Germany) and measured using a 
Monolith NT.115pico and MO. The control software was set to room temperature (25 °C) (LED/excitation power 
setting 95%, MST power setting low). Data were analysed using MO.Affinity Analysis software (version v2.2.4, 
NanoTemper Technologies) at the standard MST-on time of 5 s and presented as a bound fraction. The change in 
the normalized fluorescence (ΔFnorm) value of each point was divided by the amplitude of the fitted curve to cal-
culate the bound fraction, resulting in values ranging from 0 to 1. This approach is independent of both the initial 
Fnorm value and the amplitude of the binding curve and thus enabled us to compare the EC50 values of interactions 
with different amplitudes.
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BRet-based β-arrestin 2 recruitment assay. We used a previously described BRET-based βarr2 recruit-
ment assay26,45,48, with some modifications. Because P3 binds to intracellular receptor domains, BRET assays 
were performed using either homogenized cells or permeabilized cells. HEK-293 cells cultured in a 75 cm2 flask 
were transiently co-transfected with constructs encoding β2-AR/RLuc8 (0.1 μg) alone or together with the double 
GFP2/β-arr2 Arg393Glu, Arg395Glu mutant (4.9 μg). Homogenized/permeabilized cells were prepared 48 h after 
transfection. Homogenized cells were washed twice with DPBS, scraped from 75 cm2 tissue culture flasks using 
cell scrapers (Falcon) and pelleted by centrifugation at 1,000 rpm for 5 minutes. The cell pellets were resuspended 
in 1 mL of DPBS supplemented with Ca2+/Mg2+, 1 g/L glucose, and 36 mg/L sodium pyruvate, incubated on ice 
for 10 minutes, and homogenized using a glass homogenizer (BDH).
Cells were permeabilized by adding 0.01% Triton™ X-100 in DPBS and incubating for 15 minutes at 37 °C. 
Homogenized/permeabilized cells were then diluted in supplemented DPBS such that the luminescence sig-
nal in 180 μL of DPBS containing homogenized/permeabilized cells distributed in 96-well microplates (white 
Optiplate; Packard BioScience, Meriden, CT, USA) was approximately 30,000 arbitrary units. After the coelen-
terazine 400a was injected (final concentration of 5 μM), the luminescence signals were recorded (TriStar LB 942 
microplate reader, Berthold Technologies, Bad Wildbad, Germany). Signals at 410 nm and 515 nm were recorded 
sequentially, and the 515/410 ratio (BRET2 signal) was calculated. The results were reported in milliBRET units 
(mBU); BRET2 ratio × 1000. The expression levels of RLuc8- and GFP2-tagged constructs in each experiment 
were assessed by measuring the total luminescence and fluorescence as described above. Determinations were 
performed in triplicate. The obtained data were transferred to GraphPad Prism 7.0 (GraphPad software, San 
Diego, CA, USA) and BRET EC50/IC50 values (nM ± SEM) generated using a sigmoidal dose-response curve fit.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information Files.
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